RespiriTB | Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
01-05-2019
-30-04-2027
Show more information
Organisation
JANSSEN PHARMACEUTICA NV